内容紹介
Clinicopathological Features and Outcomes of Treatment for HER2 Positive Gastric Cancer
Summary
In March 2011, trastuzumab was approved for treating human epidermal growth factor receptor 2(HER2)positive advanced gastric cancer(AGC)in Japan. Therefore, all patients with AGC should be evaluated for HER2 status. In this study, we analyzed the clinicopathological features and current status of treatment in HER2 positive gastric cancer. One hundred 6 gastric cancer patients were examined for HER2 expression in our hospital between March 2011 and August 2014. Sixteen patients(15.1%)were HER2 positive. There was no correlation between HER2 status and age, sex, and location of tumor; however, HER2 positivity was significantly more frequent in patients with intestinal type tumors and had a tendency towards being more frequent in patients with macroscopic types 0, 1 or 2. Trastuzumab was administered to 10 patients with HER2 positive AGC. The total number of doses of trastuzumab was 1 to 44(median 7.5), and the therapeutic effect of trastuzumab combination chemotherapy was 1 patient with a complete response and 4 with a partial response. Adverse events due to trastuzumab were not observed. The incidence of HER2 over-expression was 15.1%, and trastuzumab combination chemotherapy was relatively safe and effective.
要旨
2011年3月,HER2陽性進行再発胃癌に対してtrastuzumab(Tmab)が承認され,治療方針決定の際にHER2の検索が必要となった。今回,当院におけるHER2陽性胃癌の臨床病理学的特徴および治療の現状について検討した。2011年3月～2014年8月に当院でHER2発現を検索した106例を対象とした。HER2陽性は16例(15.1%)であった。HER2陽性例は陰性例と比較し,年齢,男女比,原発部位に差を認めなかったが,組織型は分化型が,肉眼型としては限局型が多い傾向を認めた。10例にTmab併用化学療法が行われ,HER2投与回数は1～44(中央値7.5)回,最大治療効果はCR 1例,PR 4例であった。Tmabに特徴的な有害事象を認めなかった。当院におけるHER2陽性率は15.1%と既報と同程度で,またTmab併用化学療法は安全かつ有効と思われた。
目次
Summary
In March 2011, trastuzumab was approved for treating human epidermal growth factor receptor 2(HER2)positive advanced gastric cancer(AGC)in Japan. Therefore, all patients with AGC should be evaluated for HER2 status. In this study, we analyzed the clinicopathological features and current status of treatment in HER2 positive gastric cancer. One hundred 6 gastric cancer patients were examined for HER2 expression in our hospital between March 2011 and August 2014. Sixteen patients(15.1%)were HER2 positive. There was no correlation between HER2 status and age, sex, and location of tumor; however, HER2 positivity was significantly more frequent in patients with intestinal type tumors and had a tendency towards being more frequent in patients with macroscopic types 0, 1 or 2. Trastuzumab was administered to 10 patients with HER2 positive AGC. The total number of doses of trastuzumab was 1 to 44(median 7.5), and the therapeutic effect of trastuzumab combination chemotherapy was 1 patient with a complete response and 4 with a partial response. Adverse events due to trastuzumab were not observed. The incidence of HER2 over-expression was 15.1%, and trastuzumab combination chemotherapy was relatively safe and effective.
要旨
2011年3月,HER2陽性進行再発胃癌に対してtrastuzumab(Tmab)が承認され,治療方針決定の際にHER2の検索が必要となった。今回,当院におけるHER2陽性胃癌の臨床病理学的特徴および治療の現状について検討した。2011年3月～2014年8月に当院でHER2発現を検索した106例を対象とした。HER2陽性は16例(15.1%)であった。HER2陽性例は陰性例と比較し,年齢,男女比,原発部位に差を認めなかったが,組織型は分化型が,肉眼型としては限局型が多い傾向を認めた。10例にTmab併用化学療法が行われ,HER2投与回数は1～44(中央値7.5)回,最大治療効果はCR 1例,PR 4例であった。Tmabに特徴的な有害事象を認めなかった。当院におけるHER2陽性率は15.1%と既報と同程度で,またTmab併用化学療法は安全かつ有効と思われた。